PEOPLE - Biotrin Holdings makes appointment:
This article was originally published in Clinica
Biotrin Holdings, a US diagnostics company, has appointed Scott Garrett to its board of directors. Mr Garrett is CEO of Garrett Capital Advisors and was a former chairman and CEO of Dade Behring.
You may also be interested in...
Formal dispute resolution was key element in four-month turnaround from rejection by US FDA to approval for golodirsen, the second Sarepta DMD drug to clear the agency after appearing to have minimal prospects.
Correvio’s attempt to move vernakalant from 'clinical hold' to 'FDA approved' was a huge long shot. But the advisory committee vote – and looming FDA rejection – are another indication that real-world data is not a panacea.